Status:
COMPLETED
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
Lead Sponsor:
Sanofi
Conditions:
Arthroplasty, Replacement, Hip
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study is performed to confirm the optimal dose for THR (total hip replacement).
Eligibility Criteria
Inclusion
- Patients undergoing elective primary THR (total hip replacement) surgery
Exclusion
- Patient with risk of clinical significant bleeding
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT00349180
Start Date
June 1 2006
Last Update
March 27 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Tokyo, Japan